Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2017/11/010716
CTRI/2017/11/010716
Active, not recruiting
Phase 2

A Randomized Placebo Controlled Prospective Phase II Clinical Study of an Ayurvedic coded drug AYUSH D on Glycemic Control in Prediabetic Subjects - RAPD

Incharge0 sites0 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Not specified
Sponsor
Incharge
Status
Active, not recruiting
Last Updated
4 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Sponsor
Incharge

Eligibility Criteria

Inclusion Criteria

  • •1\.Subjects of either sex, 18\-60 years
  • •2\.Pre\-diabetic subjects with HbA1c of 5\.7\-6\.4%.
  • •3\.Subjects who agree to participate in the study and submit a written informed consent form

Exclusion Criteria

  • •1\.Known Cases of DM, both type I and II.
  • •2\.Past history of gestational diabetes
  • •3\.Subjects on β\-blockers, thiazide diuretics, corticosteroids, HRT.
  • •4\.Uncontrolled Hypertensive subjects(with or without medication \> 140/90 mmHg)
  • •5\.Any unstable Heart disease
  • •6\.Patients with concurrent Hepatic Dysfunction (defined as AST and/or ALT \> 2 times of the upper normal limit) or Renal Dysfunction (defined as S. creatinine \> greater than ULL),uncontrolled Pulmonary Dysfunction (asthmatic and COPD subjects) .
  • •7\.Pregnant / Lactating women.
  • •8\.Alcoholics and/or drug abusers
  • •9\.Patients with evidence of malignancy
  • •10\.Patients suffering from major systemic illness necessitating long term drug treatment (Rheumatoid arthritis, Psycho\-Neuroendocrinal disorders, etc.)

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not yet recruiting
Phase 4
A study of a food supplement to reverse feeling of tiredness after a viral infectioHealth Condition 1: G933- Postviral fatigue syndrome
CTRI/2023/08/056433Carmel Research Consultancy Private Limited
Active, not recruiting
Phase 1
A Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosison-alcoholic Steatohepatitis (NASH) CirrhosisMedDRA version: 20.0Level: LLTClassification code: 10009214Term: Cirrhosis of liver without mention of alcohol Class: 10019805Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
CTIS2024-510627-20-00Madrigal Pharmaceuticals Inc.700
Active, not recruiting
Phase 1
A Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosison-alcoholic Steatohepatitis (NASH) CirrhosisMedDRA version: 20.0Level: LLTClassification code 10009214Term: Cirrhosis of liver without mention of alcoholSystem Organ Class: 10019805 - Hepatobiliary disordersTherapeutic area: Diseases [C] - Digestive System Diseases [C06]
EUCTR2022-002279-13-DEMadrigal Pharmaceuticals, Inc.700
Active, not recruiting
Phase 1
A Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis
EUCTR2022-002279-13-FRMadrigal Pharmaceuticals, Inc.700
Completed
Not Applicable
A Phase 1, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses Oral Doses of APX001, to Investigate the Effect of Food on APX001 and to Investigate the Drug-Drug Interaction Potential of APX001
NL-OMON45345Amplyx Pharmaceuticals, Inc.46